Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.53 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8042623 | 1.00 | SPHK1 (0.53) | SPHK1HSD11B2GPR119BRD4EPHX2 | |
| SCHEMBL18959562 | 0.93 | SPHK1 (0.60) | SPHK1HSD11B2BRD4CES2CHRM2 | |
| SCHEMBL9915254 | 0.91 | SPHK1 (0.61) | SPHK1HSD11B2BRD4CES2CHRM2 | |
| SCHEMBL18959559 | 0.91 | SPHK1 (0.61) | SPHK1HSD11B2BRD4CES2CHRM2 | |
| SCHEMBL17020101 | 0.91 | SPHK1 (0.61) | SPHK1HSD11B2BRD4CES2CHRM2 | |
| SCHEMBL16070969 | 0.91 | SPHK1 (0.61) | SPHK1HSD11B2BRD4CES2CHRM2 | |
| SCHEMBL16071281 | 0.91 | SPHK1 (0.58) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL10211328 | 0.86 | SPHK1 (0.54) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL11956427 | 0.86 | SPHK1 (0.54) | SPHK1HSD11B2BRD4CHRM2CHRM1 | |
| SCHEMBL24304399 | 0.86 | SPHK1 (0.58) | SPHK1HSD11B2BRD4EPHX2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| WO-2009081959-A1 | PROCESS FOR PRODUCTION OF 4-(SUBSTITUTED PHENYL)HEXAHYDROPYRIDO[2,1-C][1,4]OXAZIN-6-ONE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | PSEN1, APP, BACE1 | SPHK1 253/4885HSD11B2 368/4885GPR119 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.